BioCryst Pharmaceuticals (BCRX) is back in focus after the FDA cleared a supplemental New Drug Application for an oral pellet version of ORLADEYO for hereditary angioedema prophylaxis in adults and adolescents.
Investors have reacted quickly to the FDA decision, with BioCryst Pharmaceuticals’ share price gaining 3.94% on the day to US$8.57 and registering a 5.80% 7 day share price return. The 1 year total shareholder return of 26.78% and 3 year total shareholder return of 41.19% suggest momentum has been building over time, despite a softer 90 day share price return that declined 5.51%.
Scan beyond BioCryst Pharmaceuticals and see how other rare disease players are setting up by reviewing our curated list of 19 high quality undiscovered gems.
The FDA win has clearly nudged BioCryst Pharmaceuticals higher, yet the mixed recent returns hint that sentiment is doing some of the lifting. How does that balance against what the current valuation implies for the business itself?
Most Popular Narrative: 60% Undervalued
On Simply Wall St’s most followed narrative, BioCryst Pharmaceuticals screens as materially undervalued, with a fair value of $21.30 against the last close of $8.57. That gap rests on some ambitious assumptions about how the hereditary angioedema portfolio and broader rare disease pipeline translate into cash generation over time.
Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.
Anticipated approval and launch of new indications such as ORLADEYO granules for pediatric patients and expanded use in HAE with normal C1 inhibitor broadens the addressable market in an environment of growing global healthcare spending on rare disease therapies, which should further increase long-term revenues and earnings visibility.
See why 29 investors see BioCryst Pharmaceuticals as 60% undervalued.
The fair value estimate in this storyline uses a 7.8% discount rate and points to BioCryst Pharmaceuticals trading at roughly a 60% discount to that $21.30 figure. That disconnect reflects expectations that an HAE franchise led by ORLADEYO, plus newer assets like navenibart and early stage programs, can support both higher sales and a shift from the current $384.7 million loss toward profitability.
Analysts feeding into this view model annual revenue growth of about 6.9% and expect earnings to move from losses today to a profit over the next three years, which underpins the implied valuation uplift from today’s $2.1b market cap. At the same time, the narrative flags real pressure points, including heavy dependence on a single product, rising HAE competition and negative shareholders’ equity, so the fair value is not presented as a low risk outcome.
The spread between the last close and the narrative fair value leaves a wide range of possible interpretations for investors, from a margin of safety to a sign that the market is applying a steep discount for funding risk, dilution history and execution uncertainty around the next wave of trials.
Result: Fair Value of $21.30 (UNDERVALUED)
Still, the whole BioCryst Pharmaceuticals story leans heavily on ORLADEYO, so tougher HAE competition or any product setback could quickly challenge that 60% undervalued narrative.
Find out about the key risks to this BioCryst Pharmaceuticals narrative.
Next Steps
With BioCryst Pharmaceuticals pulling focus again, the real edge comes from reading the data yourself and deciding quickly where you stand on the balance of risks and upside. To weigh both sides of the current debate, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond BioCryst Pharmaceuticals?
If you only stick with one opportunity, you risk missing other setups that fit your style even better. Cast the net wider with targeted screeners.
- Hunt for potential mispricings by scanning companies that combine quality fundamentals with appealing valuations through the 35 high quality undervalued stocks.
- Lock in more predictable cash flows by focusing on businesses with resilient payout profiles using the 4 dividend fortresses.
- Dial down portfolio stress by filtering for resilient businesses with sturdier balance sheets and steady fundamentals inside the list of solid balance sheet and fundamentals (23 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com